PEIJIA-B

ZYLOXTB02190 · Medical DevicesChina

70% matchPublic

Zylox-Tonbridge Medical Technology Co., Ltd. is a global medical device firm specializing in neurovascular and peripheral vascular interventional technologies. Their comprehensive product line for treating ischemic stroke includes the ThromBite Clot Retriever, designed to extract clots from major brain vessels, as well as aspiration and balloon guiding catheters. For peripheral vascular conditions, they offer the ZENFLEX Pro Drug-eluting Stent System for managing complex and recurring symptomatic lesions, the self-expanding ZENFlex Peripheral Stent System for deployment in the iliac, superficial femoral, and proximal popliteal arteries, and drug-coated Percutaneous Transluminal Angioplasty (PTA) Balloon Catheters for treating arterial stenoses or blockages in these same regions. Their neurovascular offerings further extend to Ton-Bridge extra soft coils, utilized for the endovascular embolization of intracranial aneurysms and other cerebral vascular malformations like arteriovenous malformations (AVMs) and fistulae. Supporting these are a range of microcatheters (for coiling or selective agent delivery), distal access and intracranial PTA balloon catheters, vascular snares, and IVC filter snare retrieval kits. Established in 2012, Zylox-Tonbridge Medical Technology Co., Ltd. maintains its headquarters in Zhejiang, People's Republic of China.

Jenscare Scientific Co., Ltd. operates as a medical technology enterprise dedicated to advancing interventional therapies for structural heart conditions within the People's Republic of China. Among its pipeline, the company features LuX-Valve, an investigational transcatheter tricuspid valve replacement (TTVR) system designed for patients suffering from severe tricuspid regurgitation who face elevated surgical risks. Additionally, Ken-Valve represents another key product candidate, a transcatheter aortic valve replacement (TAVR) aimed at addressing severe aortic regurgitation, often co-occurring with aortic stenosis. The applications of Jenscare's portfolio extend to a range of structural cardiac maladies, including disorders of the tricuspid, aortic, and mitral valves, as well as heart failure. Founded in 2011, the company maintains its principal place of business in Ningbo, People's Republic of China.

Keystone Heart was an Israeli medical-device company that developed cerebral embolic protection systems, including the TriGuard device, to help prevent debris from reaching the brain during transcatheter heart procedures such as TAVR. It served interventional cardiologists and structural-heart patients undergoing catheter-based valve interventions.

Venus Medtech (Hangzhou) Inc., together with its subsidiaries, engages in the research, development, manufacturing, and sale of bioprosthetic heart valves in Mainland China and internationally. The company’s offers transcatheter aortic heart valve replacement products, such as VenusA-Valve, VenusA-Plus, VenusA-Pro, and VenusA-Deluxe; and VenusP-Valve, a transcatheter pulmonary valve system to treat the patients suffering with moderate to severe pulmonary regurgitation with or without right ventricular outflow tract stenosis. It also develops Venus-Vitae, a balloon-expandable dry-tissue product; Venus-PowerX, a self-expanding dry-tissue product; Cardiovalve, a transcatheter valve replacement system for the treatment of patients with mitral regurgitation and in pivotal clinical trial for the treatment of patients with tricuspid regurgitation; Liwen RF, a radiofrequency ablation system for the treatment of hypertrophic cardiomyopathy; and renal artery denervation ablation system for the treatment of hypertension. In addition, the company offers procedural accessories comprising catheter sheath product and balloon catheter. Venus Medtech (Hangzhou) Inc. was incorporated in 2009 and is headquartered in Hangzhou, the People’s Republic of China.

MP CARDIOFLOW-B02160 · Medical DevicesChina

68% matchPublic

MicroPort CardioFlow Medtech Corporation is a medical technology firm dedicated to the comprehensive research, development, and commercialization of advanced transcatheter and surgical therapies for structural heart conditions. Operating primarily within the People's Republic of China, its innovative product line includes the Vitaflow Aortic Valve System, Alwide Balloon Catheter, and Alpass Introducer Set, specifically engineered to treat aortic, mitral, tricuspid, and surgical valve disorders. The company also supplies a range of essential procedural accessories. MicroPort CardioFlow Medtech, which commenced operations in 2010, maintains its corporate headquarters in Shanghai, China.

MICROPORT NEURO02172 · Medical DevicesShanghai, China

68% matchPublic

Established in 2004 and headquartered in Shanghai, People's Republic of China, MicroPort NeuroTech Limited is dedicated to the research, development, manufacturing, and global commercialization of neuro-interventional medical devices. The company's diverse product portfolio addresses various cerebrovascular conditions. For treating hemorrhagic stroke, it offers the NUMEN coil embolization system, the NUMEN FR coil detachment system, the Tubridge flow-diverting stent, the Willis intracranial stent graft system, and the Rebridge intracranial visualized stent. Additionally, MicroPort NeuroTech supplies the APOLLO intracranial arterial stent system for intracranial atherosclerotic disease, as well as the Bridge rapamycin target eluting vertebral artery stent system specifically designed for cerebral atherosclerotic stenosis. To address acute ischemic stroke, the company provides the Neurohawk stent thrombectomy device and the Tigertriever adjustable stent retriever.